Press ReleaseView printer-friendly version << Back
XBiotech Wins “Commercial Real Estate Award for Industrial Development” for its Headquarters in Austin, Texas
The acclaimed “open air” facility is home to XBiotech’s proprietary True Human™ therapeutic antibody discovery and manufacturing platform. True Human™ antibodies are not commercially produced or marketed anywhere else in the world (all currently available/marketed therapeutic antibodies are either of animal origin or have been modified from the original human sequences in attempt to target specific diseases. Modified antibodies differ from antibodies that the human body creates*).
*Currently marketed biologic antibody treatments are classified as either “Humanized” or “Fully Human”. “Humanized” antibodies have been sourced from non-human species and modified to become more similar to human antibodies. https://en.wikipedia.org/wiki/Humanized_antibody “Fully Human” antibodies are derived from either transgenic mice or developed from human gene sequences that are modified to create antibody drug. When either “Humanized” or so-called “Fully Human” antibodies are introduced into the human bloodstream, the immune system can recognize this as foreign and react to reject them, and these antibodies can cause various side effects. https://en.wikipedia.org/wiki/Monoclonal_antibody
XBiotech’s True Human™ antibodies are sourced from humans and derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human™ antibodies have the potential to harness the body’s natural immunity to fight disease with a high degree of safety, efficacy, and tolerability.
XBiotech’s state-of-the-art bioreactor technology replaces the complex, extremely expensive plant and equipment infrastructure that is used by other producers of antibody therapeutics. This technology allows
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our
Source: XBiotech Inc.